Skip to main content

Advertisement

Table 5 Prognostic factors in univariate analysis for progression free survival (PFS) and Overall Survival (OS). Data reported are the median survival time for the various groups and the statistical significance

From: Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy

  3DCRT p VMAT p
Overall survival
 Agea a: 1.33 ± 0.09 b: 1.06 ± 0.19 0.04 a: 1.59 ± 0.23 b: 1.25 ± 0.21 0.12
 KPSb a: 1.06 ± 0.50 b: 2.03 ± 0.53 <0.001 a: 1.03 ± 0.09 b: 2.95 ± 0.51 <0.001
 Histologyc a: 3.11 ± 0.60 b: 1.11 ± 0.06 <0.001 a: 3.62 ± 0.39 b: 1.25 ± 0.09 <0.001
 EORd a: 1.82 ± 0.31 b: 1.02 ± 0.04 <0.001 a: 2.68 ± 0.44 b: 1.19 ± 0.12 <0.001
 MGMTe a: 1.19 ± 0.06 b: 1.48 ± 0.45 0.002 a: 1.23 ± 0.13 b: 1.99 ± 0.27 0.009
Progression free survival
 Agea a: 1.10 ± 0.11 b: 0.82 ± 0.25 0.02 a: 1.37 ± 0.24 b: 0.97 ± 0.08 0.06
 KPSb a: 0.86 ± 0.04 b: 2.01 ± 0.44 <0.001 a: 0.83 ± 0.09 b: 2.78 ± 0.59 <0.001
 Histologyc a: 2.77 ± 0.57 b: 0.93 ± 0.05 <0.001 a: 3.51 ± 0.42 b: 0.99 ± 0.09 <0.001
 EORd a: 1.68 ± 0.34 b: 0.83 ± 0.06 <0.001 a: 2.58 ± 0.5 b: 0.92 ± 0.16 <0.001
 MGMTe a: 0.95 ± 0.04 b: 1.40 ± 0.36 0.02 a: 0.98 ± 0.12 b: 1.70 ± 0.44 0.02
  1. Abbreviations: 3DCRT 3 dimensional conformal radiotherapy, VMAT volumetric modulated arc therapy
  2. aa:<70 or b:>70 years
  3. ba:<80 vs b:>80
  4. ca: Grade III glioma(anaplastic astrocytoma, Anaplastic oligodendroglioma, anaplastic oligoastrocytoma) vs b: Glioblastoma
  5. da: Gross total resection vs b: Partial resection or biopsy
  6. ea: MGMT negative or b: positive